Christopher Rovaldi is VP at ACCELERON PHARMA INC (XLRN). They have made 6 open-market trades across 2 companies since 2017, most recently 2025-02-18.
CIK 0001706040
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KROS | SELL | 2022-04-06 | 2022-04-08 | $65.00 | $112K | -7.3% | -32.0% | -54.1% |
| KROS | SELL · 10b5-1 | 2022-04-01 | 2022-04-05 | $57.49 | $50K | -1.6% | -19.8% | -54.2% |
| XLRN | SELL | 2018-04-03 | 2018-04-04 | $38.34 | $245K | -2.3% | -6.2% | +22.7% |
| XLRN | SELL | 2018-01-12 | 2018-01-17 | $45.00 | $495K | -2.1% | -7.1% | -16.0% |
| XLRN | SELL | 2018-01-02 | 2018-01-04 | $42.42 | $157K | +4.6% | -9.5% | -10.8% |
| XLRN | SELL | 2017-09-12 | 2017-09-14 | $38.41 | $538K | -11.5% | -4.2% | -5.1% |
| XLRN | SELL | 2017-09-12 | 2017-09-14 | $38.32 | $488K | -11.5% | -4.2% | -5.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.